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BAFF = B cell activating factor belonging to the TNF superfamily; BCR = B cell antigen receptor; Btk = Bruton’s tyrosine kinase; BLC = B lympho-
cyte chemokine; CXCR = CXC receptor; RA = rheumatoid arthritis; xid = X-linked immunodeficiency.
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Introduction
Rheumatoid arthritis (RA) is a complex disease of
unknown etiology. Decades of research into the pathogen-
esis of the disease have elucidated a number of the key
pathways involved in the generation of the disease state.
From this research it is clear that many cell populations
are involved in disease pathogenesis. These include
B cells, T cells, dendritic cells, macrophages, monocytes,
and fibroblasts. The exact contribution of each of these
cell types in RA is unclear but it is likely that the resultant
disease is due to significant interplay among these cell
populations [1]. The observation in clinical trials that
depletion of B cells from RA patients results in a signifi-
cant therapeutic effect suggests that B cells play an
important role in disease pathogenesis [2,3].
The observation that B cell depletion in RA patients has
been efficacious in initial clinical trials suggests that other
B cell targeted therapies may also be of benefit in RA.
Molecular dissection of the pathways that regulate B cell
development and function has identified many possible
avenues, apart from B cell depletion, for modulating B cell
function in RA patients. These include strategies that are
aimed at inhibiting B cell signaling and/or B cell trafficking.
Although we briefly touch on the state of B cell depletion
techniques, the main thrust of this article is to discuss
some of the more prominent targets that allow modulation
of the B cell response.
B cell depletion
The technology to deplete B cells in RA patients is already
clinically validated. The ability to deplete B cells selectively
in RA patients was made possible through the develop-
ment of rituximab. Known commercially as MabThera®/
Rituxan® (Roche Pharmaceuticals, Basel, Switzerland;
Genentech, South San Francisco, USA; IDEC Pharma-
ceuticals, San Diego, USA) and marketed globally for the
treatment of malignant B cell lymphoma, rituximab is a
chimeric human/mouse monoclonal antibody that targets
the CD20 molecule found on the surface of B cells [4].
The CD20 molecule is a 32kDa nonglycosylated phos-
phoprotein that is present on B cells at all stages of devel-
opment before plasma cell differentiation. CD20 is not
found on other cell types, including stem cells [5]. Ritux-
imab binds to the CD20 molecule on the surface of
B cells and facilitates the depletion of B cells from patients
largely by invoking host effector mechanisms [6,7]. Initial
clinical trials in RA patients indicated that circulating
B cells are undetectable after a brief dosing regimen with
rituximab [2]. The treatment is well tolerated, and develop-
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Abstract
The role of B cells in rheumatoid arthritis (RA) has been debated for decades. However, recent clinical
trial data indicating that depletion of B cells in RA patients is of therapeutic benefit has validated the
importance of this cell type in the pathogenesis of the disease. Elucidation of the molecular basis of
B cell development and activation has allowed the identification of a number of possible therapeutic
targets that are appealing for drug development. This review discusses briefly a number of these
molecules and the rationale for targeting them for the treatment of RA.
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ment of antibody responses against the rituximab mole-
cule is low [2]. Rituximab treatment in RA is discussed at
length elsewhere in this supplement.
Although rituximab is highly effective at depleting B cells,
other reagents for the depletion of B cells are currently
under development. Some of these agents could be applic-
able to indications outside oncology. Among these drugs in
development are other antibodies that target the CD20
molecule. One example of these is Humax-CD20 (currently
under development; Genmab, Copenhagen, Denmark). This
molecule differs from rituximab in that it is a fully human
monoclonal antibody produced in transgenic mice, in which
the mouse genes for creating antibodies have been
inactivated and replaced by human antibody genes [8].
The CD19 molecule represents another attractive target for
future B cell depletion reagents. Its expression is restricted
to B cells and follicular dendritic cells. CD19, like CD20, is
present at all stages of B cell development up until differen-
tiation to plasma cells [9]. A molecule is currently being
developed that targets both CD19 and CD3, found on
B cells and T cells, respectively. This recombinant bi-
specific antibody (bscCD19×CD3) is composed of two
single chain antibodies each against the individual target
and is aimed at inducing T cell mediated depletion of
B cells [10]. Initial cell culture experiments with the anti-
body indicate that the molecule is capable of inducing
T cell mediated killing of normal peripheral B cells [11].
Blocking B cell activation
The molecular signaling pathways involved in the activa-
tion of B cells are rapidly becoming elucidated [12]. From
this work a number of potential targets for modulating
B cell function have been identified. Some of these mole-
cules and the rationale for targeting them in RA or other
autoimmune disorders are discussed below.
Bruton’s tyrosine kinase
Bruton’s tyrosine kinase (Btk) plays a key role in B cell
development and activation [13]. The maturation and
response of B cells to antigen is regulated by the cell
surface complex called the B cell antigen receptor (BCR)
[14]. The interaction of antigens with the BCR activates
signaling pathways through nonreceptor protein tyrosine
kinases, including the Tec family member Btk [12]. The
activation of these signaling pathways is required for
proper development and function of B cells, and Btk plays
a central role in this [15].
The importance of Btk in the activation process is demon-
strated most clearly by mutations that inactivate the kinase
function of the molecule. Loss of function mutations in Btk
affect B cell development and B cell activation in response
to antigen [16]. In humans this type of mutation results in
the disease X-linked agammaglobulinemia [16,17]. This
disorder is characterized by the absence of mature B cells
in the periphery and a serious deficiency of serum antibodies
[18]. In mice, Btk inactivation results in a disorder called
X-linked immunodeficiency (xid) [19,20]. The murine dis-
order results in an approximately 50% reduction in the
number of mature B cells. In addition, the xid B cells
present are functionally abnormal in that BCR signaling is
severely compromised. Further genetic experiments have
shown that partial replacement of Btk activity (25%) in xid
animals is sufficient to normalize B cell development but
not BCR signaling [21]. This result strongly suggests that
the degree of Btk function is critically important in allowing
effective B cell activation in response to antigen. That
modulation of Btk function can allow normal development
of B cells but not be sufficient for B cell activation leads to
the compelling hypothesis that a complete block in Btk
protein kinase function is not required to impair B cell signal-
ing, and a window may exist between halting B cell develop-
ment and reducing B cell signaling. These data suggest that
targeting the kinase function of Btk could result in desensiti-
zation of B cell signaling and possibly provide a therapeutic
effect in autoimmune disorders, including RA.
CD19
CD19 is a 95kDa member of the immunoglobulin super-
family expressed on B cells during most stages of devel-
opment until plasma cell differentiation. CD19 is part of a
multimolecular complex called the B cell coreceptor [9].
CD19 regulates the intrinsic B lymphocyte signaling
thresholds [22]. CD19 functions to mediate the amplifica-
tion of Src family protein kinase activity involved in BCR
signaling and plays a crucial role in the pathways that reg-
ulate intrinsic and antigen receptor induced signals [23].
CD19 mediates this signal modulation through a complex
series of phosphorylation events, referred to as progres-
sive amplification [24]. Experiments addressing the func-
tion of CD19 in vivo suggest that therapies that inhibit
CD19 function might be therapeutic in RA and other
autoimmune disorders. Specifically, an elegant series of
genetic and molecular experiments have shown that the
level of functional CD19 is critical for B cell activation.
Using genetically modified mice, it was demonstrated that
mice that are deficient for CD19 are hyporesponsive to
BCR signaling [25]. In contrast, animals that over-express
CD19 develop spontaneous autoimmunity [26]. This
finding is even more interesting in light of the fact that
patients with certain autoimmune disorders exhibit an
increase in CD19 levels comparable with that required to
induce autoimmunity in mice [27]. These findings suggest
that therapies that inhibit CD19 function may be useful in
the treatment of autoimmune disorders.
B cell activating factor
The B cell activating factor belonging to the TNF super-
family (BAFF; BlyS, TALL-1, THANK) molecule is a
homotrimer of the tumor necrosis factor superfamily that isS9
found either on the cell surface as a type II transmembrane
protein or as a soluble molecule [28,29]. BAFF is pro-
duced by macrophages, monocytes and dendritic cells,
and plays a key role in B cell survival, maturation and acti-
vation through its interaction with its receptors TACI,
BAFF-R and BCMA [30,31]. Several lines of evidence
suggest that BAFF plays a role in the induction of auto-
immunity. Transgenic mice engineered to over-express
BAFF break tolerance and develop autoantibodies, includ-
ing anti-DNA antibodies and rheumatoid factor [32,33].
This autoimmune response results in the development of a
systemic lupus-like condition. Furthermore, increased
levels of BAFF have been detected in the sera of patients
with various autoimmune diseases including systemic
lupus erythematosus and RA, further implicating this mole-
cule in the pathology of the disease [34,35].
The mechanism through which BAFF appears to mediate
B cell activation is qualitatively different from that
observed with CD19 and Btk. In contrast to Btk and
CD19, BAFF does not function to potentiate the activa-
tion of B cells directly through enhancement of BCR sig-
naling. Instead, the proliferation signal that is mediated by
BAFF results in more cells surviving to enter the cell
cycle, rather than the actual costimulation of B cells [36].
The prevailing hypothesis is that pathologic concentra-
tions of BAFF can overcome the negative selection of
autoreactive B cells in the periphery. These autoreactive
B cells then survive and subsequently produce self-reac-
tive antibodies. Based on this hypothesis, reagents that
reduce the effective concentration of BAFF either through
interaction with BAFF itself or one or more of its recep-
tors could be expected to be of clinical benefit in the
treatment of RA and other autoimmune disorders.
Blocking B cell trafficking
The trafficking of B cells is critical for proper B cell develop-
ment and activation. The molecules responsible for B cell
trafficking are called chemokines [37]. This large family of
molecules promotes the trafficking of different cell types via
concentration gradient attraction [38]. The chemokine
system has been shown to play a key role in mediating
inflammatory cell infiltration. Several B cell associated
chemokines have been described. These molecules func-
tion to promote B cell maturation by directing B cell localiza-
tion to the germinal centers as well as the localization of
B cells to sites of inflammation [39]. An ability to inhibit the
function of chemokines that are involved in B cell localiza-
tion could allow downregulation of both the local and sys-
temic immune responses. The most well characterized
B cell chemokine system is B lymphocyte chemokine (BLC)
and its receptor CXC receptor (CXCR)5.
B lymphocyte chemokine/CXC receptor 5
The chemokine BLC, also known as BCA-1 and CXCL13,
is constitutively produced by stromal cells in lymphoid
tissue and serves as a homing signal that attracts B cells
and memory T cells [39]. BLC is an 88 amino acid
member of the CXC chemokine family that interacts with
its receptor CXCR5. The CXCR5 receptor is found on all
mature B lymphocytes as well as on a subpopulation of
memory T cells [40]. Transgenic mice that have been ren-
dered deficient for either BLC or CXCR5 exhibit several
characteristics that demonstrate the important role of the
BLC/CXCR5 system in the trafficking of B cells in vivo
[41,42]. These mice lack most inguinal lymph nodes and
Peyer’s patches. Furthermore, the normal organizational
architecture observed in the spleen is disrupted in these
animals. The fact that mice deficient for the BLC signaling
system fail to organize lymphoid tissue compartments cor-
rectly has implications for the importance of the target in
RA pathogenesis. Analysis of tissues harvested from
active RA joints indicated that tissue infiltrating lympho-
cytes can be found to be arranged in sophisticated micro-
organizations identified as germinal centers, which are
normally restricted to secondary lymphoid organs
[43–49]. Examination of the expression of BLC in the syn-
ovium of RA patients suggest that the chemokine is upreg-
ulated in these tissues and the levels of expression
correlate with the level of ectopic germinal center forma-
tion and B cell aggregation [43]. These data strongly
implicate aberrant production of BLC in the formation of
these structures.
The expression of BLC and CXCR5 in germinal centers
within RA synovium suggest that therapies that effectively
target the functioning of this B cell homing system could
significantly impact on the progression of the disease by
inhibiting the formation of autoantibody producing struc-
tures within the joint. The effect of eliminating B cells from
the lymphoid structures was addressed through the use of
human synovium/severe combined immunodeficient
mouse chimeras [48]. In these experiments, treatment with
rituximab demonstrated that the presence of B cells is
required for germinal center formation and T cell activa-
tion. Taken together, these results suggest that therapies
that prevent B cell trafficking and the subsequent organi-
zation of B cells into lymphoid structures may act to inhibit
the pathology observed in RA joints.
Conclusion
Data from clinical trials indicating that B cell depletion with
rituximab is highly therapeutic, and well tolerated, in RA
patients have validated the contribution of B cells in the
pathogenesis of RA [2]. These observations will probably
lead to more therapies aimed at the modulation of B cell
responses in patients. Elucidation of the pathways that
regulate B cell development and activation has identified a
number of molecules that are attractive from a drug dis-
covery perspective. These include molecules involved in
B cell activation, survival and trafficking, as well as targets
other than CD20 for B cell depletion. In this review we
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discuss some of the most obvious of these potential
targets. The question of whether modulation of these
targets will be of therapeutic benefit in RA remains to be
determined clinically.
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